Insulin analogues versus human insulin in type 1 diabetes: direct and indirect meta-analyses of efficacy and safety (Q57547619)

1

0 references

Cassyano Januário Correr

2

0 references

Rafael Venson

3

0 references

Patrícia Rodrigues Gonçalves

4

0 references

Mariana Martins Garcia

5

0 references

Mário Sérgio Piantavini

6

0 references

Roberto Pontarolo

BJPS: Brazilian Journal of Pharmaceutical Sciences

7

0 references

publication date

September 2013

0 references

published in

0 references

volume

49

0 references

page(s)

501-509

0 references

issue

3

0 references

cites work

Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with Type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

Pre-meal insulin analogue insulin lispro vs Humulin R insulin treatment in young subjects with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

A review of human and analogue insulin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferior

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011

Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1984-82502013000300011